Compare NXDT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | CGEN |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1M | 270.4M |
| IPO Year | N/A | 2001 |
| Metric | NXDT | CGEN |
|---|---|---|
| Price | $4.88 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 125.2K | ★ 498.7K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $4.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $1.30 |
| 52 Week High | $5.49 | $3.24 |
| Indicator | NXDT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 55.14 |
| Support Level | $3.37 | $1.46 |
| Resistance Level | $4.96 | $3.24 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 35.39 | 63.73 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.